Expanding the therapeutic implication of epigenetic therapy in prostate cancer
In PCa, genetic and epigenetic modification previously shown to play a critical roles in development and progression. PCa is composed of a mixture of cells consisting of lumina, neuroendocrine and stem-like phenotypes that have activation of key signalling pathways including the androgen receptor (AR), Akt, Myc and driven by key genomic alterations including chromosomal rearrangements (TMPRSS2-ERG fusion) or silencing of the PTEN tumour suppressor by genetic and epigenetic mechanisms. Castrate-resistant prostate cancer (CRPC) represents an aggressive and incurable phenotype of prostate cancer. Patients who progress after receiving androgen deprivation therapy (ADT) have improved second-line treatments that have demonstrated increased survival benefits, but sustainable suppression of CRPC growth remains an obstacle and requires the continued development of novel treatment strategies to combat the progression of disease. The proposed project aims to investigate the influence of novel treatment therapies (HDAC and bromodomain inhibitors) on (1) their ability to target and differentiate the stem-like cells within PCa and (2) re-sensitize PCA to androgen deprivation therapy through targeting of AR full-length and ARV7 expression and cellular localization.
Candidates should have or expect to obtain a 2:1 or higher Honours degree or equivalent in a relevant biomedical or life sciences subject.
Candidates applying from countries where the first language is not English should produce evidence of their competence through a qualification such as IELTS or TOEFL score.
The minimum recommended score for the School of Medicine, Dentistry and Biomedical Science is:
• IELTS score of 6.0 with not less than 5.5 in each of the four component elements of listening, reading, speaking and writing taken within the last 2 years;
• TOEFL score of 80+ (internet basted test), taken within the last 2 years, with minimum component scores of; Listening 17, Reading 18, Speaking 20, Writing 17);
• A valid Certificate of Proficiency in English grade A or B;
• A valid Certificate of Advanced English grade A; or
• A first or upper second class honours degree from a university based in the UK, Republic of Ireland or other suitably quality assured location in a country deemed by the UK Border Agency to be majority English speaking.
For a list of English Language qualifications also accepted by the School and University please see the following link:
The English Language Unit (ELU) offers both pre-sessional and in-sessional courses in English for academic purposes and study skills. Courses vary in length and full information can be obtained from the ELU http://www.qub.ac.uk/tefl/
DEL Research Studentships
Eligibility for both fees and maintenance (£14,057 for 2015/16, 2016/17 TBC) depends on the applicants being either an ordinary UK resident or those EU residents who have lived permanently in the UK for the 3 years immediately preceding the start of the studentship.
Non UK residents who hold EU residency may also apply but if successful may receive fees only.
For further details re eligibility criteria (including academic, citizenship and residency criteria) please click on the following link: http://www.delni.gov.uk/index/further-and-higher-education/higher-education/studentfinance/he-student-info-postgrad-finance.htm
Please visit the School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, website for further details about the Centre:
When applying, please choose 'MEDICINE' as your subject area/School.